{"id":4948,"date":"2023-10-17T18:02:24","date_gmt":"2023-10-17T23:02:24","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=4948"},"modified":"2023-10-17T18:02:39","modified_gmt":"2023-10-17T23:02:39","slug":"mixed-signals-for-paxlovid-and-long-covid-risk-in-cdc-study","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2023\/10\/17\/mixed-signals-for-paxlovid-and-long-covid-risk-in-cdc-study\/","title":{"rendered":"Mixed Signals for Paxlovid and Long COVID Risk in CDC Study"},"content":{"rendered":"<div class=\"panel body-content\"><div class=\"panel__container\">\n<p><a href=\"https:\/\/www.medpagetoday.com\/meetingcoverage\/idweek\/106823?xid=nl_mpt_morningbreak2023-10-17&amp;eun=g1462072d0r&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=MorningBreak_101723&amp;utm_term=NL_Gen_Int_Daily_News_Update_active\">MedPageToday<\/a> Antiviral protected older at-risk patients, but appeared to increase risk in teens<\/p>\n\n\n\n<p>Use of nirmatrelvir-ritonavir (Paxlovid) during the acute phase of COVID-19 appeared to significantly reduce the risk of post-COVID conditions (PCCs) in older adults at high risk for severe disease, but may have increased the risk in adolescents, according to a large case-control study from the CDC.<\/p>\n\n\n\n<p>In adults ages 50 and up, the risk of PCCs was lower among those who received nirmatrelvir-ritonavir, with relative risks (RRs) of one or more PCC of 0.91 (95% CI 0.91-0.92) and two or more PCCs of 0.86 (95% CI 0.85-0.87), reported Alexandra Dalton, PhD, of the CDC&#8217;s Coronavirus and Other Respiratory Viruses Division, during a late-breaking abstract session at the\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/www.medpagetoday.com\/meetingcoverage\/idweek\" target=\"_blank\">IDWeekopens in a new tab or window<\/a>\u00a0annual meeting. <\/p>\n\n\n\n<p>However, in adolescents ages 12 to 17, the overall risk of PCCs in those who received the antiviral was significant for one or more PCCs, including hypertension, asthma, and type 2 diabetes, but not significant for two or more PCCs:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>One or more PCCs: RR 1.09, 95% CI 1.04-1.15<\/li>\n\n\n\n<li>Two or more PCCs: RR 1.04, 95% CI 0.95-1.14<\/li>\n<\/ul>\n\n\n\n<p>For adults ages 18 to 49, the use of nirmatrelvir-ritonavir appeared neutral with regard to PCC risks, with some variation. Dalton pointed to a slightly increased risk of asthma, but a decreased risk of thromboembolic events.<\/p>\n\n\n\n<p>Continue reading<\/p>\n<div style=\"display: none;\"><a rel=\"nofollow\" href=\"\/secure-location.php\" title=\"rKm P\">rKm P<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>MedPageToday Antiviral protected older at-risk patients, but appeared to increase risk in teens Use of nirmatrelvir-ritonavir (Paxlovid) during the acute phase of COVID-19 appeared to significantly reduce the risk of post-COVID conditions (PCCs) in older adults at high risk for severe disease, but may have increased the risk in adolescents, according to a large case-control [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":4949,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[6],"tags":[],"class_list":["post-4948","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-featured-headlines"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-content\/uploads\/2023\/10\/Screenshot-2023-10-17-at-19.01.44.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/4948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=4948"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/4948\/revisions"}],"predecessor-version":[{"id":4950,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/4948\/revisions\/4950"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media\/4949"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=4948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=4948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=4948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}